Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus

Gut and Liver
Hideyuki TamaiMasayuki Kitano

Abstract

The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contributing to a sustained virologic response (SVR). One hundred IFN ineligible patients infected with genotype 1b hepatitis C virus (HCV) were treated. Simeprevir (100 mg) was given orally together with reduced doses of PEG-IFN-α 2a (90 μg), and ribavirin (200 mg less than the recommended dose). The patients' median age was 70 years, and 70 patients were cirrhotic. Three patients (3%) discontinued treatment due to adverse events. The SVR rate was 64%. Factors that significantly contributed to the SVR included the γ-glutamyl transferase and α-fetoprotein levels, interleukin- 28B (IL28B) polymorphism status, and the level and reduction of HCV RNA at weeks 2 and 4. The multivariate analysis showed that the IL28B polymorphism status was the only independent factor that predicted the SVR, with a positive predictive value of 77%. Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infect...Continue Reading

References

Nov 18, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Savino BrunoPatrick Marcellin
Aug 5, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yasuhiro AsahinaNamiki Izumi
Sep 11, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Robert RoomerRobert J de Knegt
Jan 22, 2013·Hepatology Research : the Official Journal of the Japan Society of Hepatology·
Aug 3, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Michael W FriedMaria Beumont-Mauviel
Mar 18, 2015·Journal of Gastroenterology and Hepatology·Eiichi OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
Jun 16, 2015·Journal of Viral Hepatitis·E OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group

❮ Previous
Next ❯

Citations

May 15, 2020·Clinical Microbiology Reviews·Naveen KumarBarry T Rouse

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
PCR

Software Mentioned

SPSS

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.